Angiotensin Converting Enzyme (ACE) Inhibitors

Ginat, Daniel Thomas; Johnson, Jason M.

doi:10.1007/978-3-319-12715-6_43

Neuroimaging Pharmacopoeia 2015

DOI: 10.1007/978-3-319-12715-6_43

|View full text |Cite

Angiotensin Converting Enzyme (ACE) Inhibitors

Daniel Thomas Ginat

Jason M. Johnson

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 11 publications

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination

Ruf

Gera²,

Luus

et al. 1994

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The pharmacokinetics and pharmacodynamics of single oral doses of 5 mg ramipril and 6 mg piretanide administered separately and in combination were determined in a single blind, randomised, 3-period cross-over study in 24 healthy male volunteers. The peak plasma concentrations of ramipril and ramiprilat increased slightly (from 11.9 to 14.8 ng/ml, and from 6.39 to 8.96 ng/ml, respectively) as did the area under the plasma concentration-time curve of ramipril (0-4 h) and ramiprilat (0-24 h) (from 15.8 to 19.8 ng.ml-1.h, and from 63.4 to 74.6 ng.ml-1.h, respectively). The urinary excretion of ramiprilat also rose (from 6.82 to 7.73% of dose) following simultaneous treatment with piretanide. These effects were probably due to reduced first-pass metabolism of ramipril/ramiprilat to inactive metabolites. The blood pressure lowering effect, the time course of inhibition of ACE activity in plasma and the concentration-response relationship for the inhibition of plasma ACE activity were not affected by piretanide. The peak plasma concentration of piretanide was somewhat reduced (from 285 to 244 ng/ml) following simultaneous treatment with ramipril. No other pharmacokinetic parameter was affected. Piretanide increased urine flow, and sodium, chloride and potassium excretion, especially during the first 2 hours following administration. These pharmacodynamic parameters were not affected by ramipril. Thus, simultaneous administration of single oral doses of ramipril and piretanide caused modest changes in the peak and average plasma concentrations of both drugs, which did not lead to detectable alterations in the pharmacodynamic parameters measured in healthy volunteers.

show abstract

Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination

Ruf

Gera²,

Luus

et al. 1994

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Influences of the chemical structure on the activity of new inhibitory compounds of the angiotensin-converting enzyme

Siems¹,

Heder²,

Jentzsch³

et al. 1986

Experientia

View full text Add to dashboard Cite

show abstract

Angiotensin converting enzyme inhibitors

Soudijn

1982

Pharmaceutisch Weekblad Scientific Edition

View full text Add to dashboard Cite

Inhibition of angiotensin converting enzyme (ACE) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally active ACE inhibitor and the structure-activity relationship of captopril analogues are described. Some side effects of captopril were attributed to the presence of an SH-group in the molecule. This led to the development of a series of non-mercapto ACE inhibitors derived from captopril. One of them, enalapril, a potent ACE inhibitor with a long duration of antihypertensive action, is now tested in clinical trials.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Angiotensin Converting Enzyme (ACE) Inhibitors

Cited by 11 publications

References 5 publications

Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination

Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination

Influences of the chemical structure on the activity of new inhibitory compounds of the angiotensin-converting enzyme

Angiotensin converting enzyme inhibitors

Contact Info

Product

Resources

About